CN107501394B - 高特异性mmp-14底物肽及其制备方法和应用 - Google Patents
高特异性mmp-14底物肽及其制备方法和应用 Download PDFInfo
- Publication number
- CN107501394B CN107501394B CN201710462607.5A CN201710462607A CN107501394B CN 107501394 B CN107501394 B CN 107501394B CN 201710462607 A CN201710462607 A CN 201710462607A CN 107501394 B CN107501394 B CN 107501394B
- Authority
- CN
- China
- Prior art keywords
- mmp
- substrate peptide
- detection
- polypeptide
- washing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 48
- 239000000758 substrate Substances 0.000 title claims abstract description 35
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 title claims abstract description 24
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 20
- 238000010791 quenching Methods 0.000 claims abstract 2
- 230000000171 quenching effect Effects 0.000 claims abstract 2
- 238000005406 washing Methods 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 4
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- ZEKAXIFHLIITGV-UHFFFAOYSA-N 7-methoxycoumarin-4-acetic acid Chemical compound OC(=O)CC1=CC(=O)OC2=CC(OC)=CC=C21 ZEKAXIFHLIITGV-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract description 21
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract description 21
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 108050005238 Collagenase 3 Proteins 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102100024130 Matrix metalloproteinase-23 Human genes 0.000 description 2
- 102100026799 Matrix metalloproteinase-28 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002173 cutting fluid Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 238000007805 zymography Methods 0.000 description 2
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- GLJCJFFDYXFRQX-NRFANRHFSA-N (2s)-3-(2,4-dinitroanilino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GLJCJFFDYXFRQX-NRFANRHFSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NFOMZHGRFWXDGH-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]etho Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)O)C3=CC=CC=C3C2=C1 NFOMZHGRFWXDGH-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- -1 Fmoc-Leu-OH amino acid Chemical class 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BPOHQCZZSFBSON-KKUMJFAQSA-N His-Leu-His Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BPOHQCZZSFBSON-KKUMJFAQSA-N 0.000 description 1
- PDLQNLSEJXOQNQ-IHPCNDPISA-N His-Trp-Lys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CN=CN1 PDLQNLSEJXOQNQ-IHPCNDPISA-N 0.000 description 1
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 1
- 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 1
- 101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 description 1
- 101000595925 Homo sapiens Plasminogen-like protein B Proteins 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108700010340 Leishmanolysins Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
- 108090000560 Matrix metalloproteinase-15 Proteins 0.000 description 1
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
- 108090000561 Matrix metalloproteinase-16 Proteins 0.000 description 1
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
- 108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 1
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 1
- 108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 1
- 102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 1
- 101710082411 Matrix metalloproteinase-21 Proteins 0.000 description 1
- 108050006284 Matrix metalloproteinase-23 Proteins 0.000 description 1
- 102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 1
- 108050005214 Matrix metalloproteinase-24 Proteins 0.000 description 1
- 102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 1
- 102100024132 Matrix metalloproteinase-27 Human genes 0.000 description 1
- 108050005201 Matrix metalloproteinase-27 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102100035195 Plasminogen-like protein B Human genes 0.000 description 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明属于生物酶检测领域，具体涉及一种高特异性MMP‑14底物肽及其制备方法和应用。该底物肽具有如式I所示的结构：其中，n为4‑30的整数，F1和F2分别为荧光基团及其对应的淬灭基团。本发明的底物具有高特异性，该底物以多肽及PEG结构为基础，在基质金属蛋白酶检测及癌症检测治疗应用方面具有广阔的前景。
Description
技术领域
本发明涉及生物酶检测领域，更具体地，涉及一种高特异性MMP-14底物肽及其制备方法和应用。
背景技术
基质金属蛋白酶(matrix metalloprotease，MMPs)是一类自然进化中高度保守的，活性依赖于锌离子和钙离子的蛋白水解酶，其广泛分布于植物、脊椎动物、无脊椎动物中。目前该家族已分离鉴别出28个成员，编号分别为MMP1-28。该家族成员具有相似的结构，一般由5个功能不同的结构域组成，包括疏水信号肽序列、前肽区(保持酶原的稳定)、催化活性区(Zn2+结合位点)、富含脯氨酸的铰链区和羧基末端区(与酶的底物特异性有关)。MMPs成员在上述共同结构的基础上各有特点，不同MMPs结构中底物结合区内侧残基侧链大小不同直接导致底物结合的差异性。根据作用底物的种类以及片断同源性，MMPs可分为6类：胶原酶(MMP-1、MMP-8、MMP-13、MMP-18)；明胶酶(MMP-2、MMP-9)；间质水解酶(MMP-3、MMP-10、MMP-11)；基质水解酶(MMP-7、MMP-26)；膜型MMP(MMP-14、MMP-15、MMP-16、MMP-17、MMP-24、MMP-25)和其他分泌型MMP(MMP-19、MMP-21、MMP-23、MMP-27、MMP-28)。
MMPs的主要功能是降解细胞外基质的有效成分，在细胞迁移、血管生成、胚胎发育、动脉粥样硬化、肝肾纤维化疾病、恶性肿瘤的浸润与转移等病理生理过程中发挥重要的作用。通过对基质金属蛋白酶的检测，可以深度了解其性质及致病机理，并进一步了解病症的恶化程度，从而进行及时检测治疗。鉴于MMPs在生理和病理进程中起着关键性的作用，对于基质金属蛋白酶检测技术的研究开发是十分必要的。
MMP-14作为MMPs家中的重要一员膜蛋白，发挥着降解基底膜与细胞外基质以及调节细胞运动、生长、分化、凋亡等多种生命功能。研究表明，其在结肠癌、胃癌、乳腺癌和宫颈癌的转移与侵袭中都扮演着重要的角色。研究还发现，MMP-14参与另两个重要的MMPs家族成员MMP-2、MMP-13酶原的激活过程，而这两个蛋白酶也已被实验证实与肿瘤的侵袭和转移紧密相关，换言之，MMP-14是研究肿瘤侵袭和转移机制中非常关键的一环，对其性质的深入研究将有望揭示致病机理，实现对疾病的有效诊断和治疗。
目前常见的MMPs酶活检测方法有：荧光明胶酶检测法、明胶酶谱法、DQ明胶原位酶谱分析、高效液相色谱法、肽链修饰的荧光探针技术以及荧光分子断层成像技术。其中荧光探针技术相比其它技术具有可实现“实时、可视、定量”的高灵敏度检测的潜力，具有一定的技术优势。目前报道的肽链修饰的荧光探针主要可以分为3类：酶活性荧光成像探针、靶向探针和交联成像探针。其中基于多肽的荧光探针是研究最广的酶活性成像探针。此类成像探针的底物是基于荧光共振能量转移(fluorescence resonance energy transfer，FRET)的原理设计。FRET作为一种方便、快捷、灵敏的光学手段被广泛应用于化学分析、生物结构研究等领域，特别是在蛋白酶活性的测定中效果显著。
然而由于MMPs家族蛋白酶之间具有较明显的底物交叉活性，如何提高底物肽的特异性成为荧光类检测探针开发中的关键问题。
发明内容
本发明的目的是提供一种提高MMPs乃至酶底物特异性的方法。该法通过在底物中引入适当的linker和具有特异性结合的非底物结合肽，极大提高了酶对底物催化的特异性。
为了实现上述目的，本发明提供一种高特异性MMP-14底物肽，该底物肽具有如式I所示的结构：
其中，n为4-30的整数，F1和F2分别为荧光基团及其对应的淬灭基团优选地，n为6-24的整数，进一步优选地，n为10-15的整数。
该底物肽的序列通式可表达为：F1-PLGL-F2-AR-(PEG)n-HWKHLHNTKTFL，其中，PLGL如SEQ ID NO：1所示，HWKHLHNTKTFL如SEQ ID NO：2所示。
本发明中，F1和F2可以为常规的荧光-淬灭基团对。优选地，所述底物肽具有式II所示结构(序列通式为：(MCA)-PLGL-(Dpa)-AR-(PEG)n-HWKHLHNTKTFL)，或具有式III所示结构。
其中，p和q均为为4-30的整数，优选地，p和q均为6-24的整数，进一步优选地，p和q均为10-15的整数。具有优选长度聚乙二醇linker的底物肽具有更高的催化特异性。
本发明还提供上述高特异性MMP-14底物肽的制备方法，该制备方法包括如下步骤：
合成顺序：从C端到N端；
(1)将2-氯三苯甲基氯树脂进行溶胀；
(2)完成第一个Fmoc保护的氨基酸的连接，随后重复脱保护、检测、洗涤、加入Fmoc保护的氨基酸进行缩合、检测、洗涤的步骤，按所设计序列连入相应的氨基酸，最后接MCA；
(3)抽干并洗涤树脂；
(4)用切割液将多肽从树脂上切割下来；
(5)将裂解液用氮气吹干，多肽用乙醚洗涤，然后常温干燥；
(6)使用HPLC对粗品进行分析提纯。
上述方法的具体步骤为本领域技术人员公知。
例如，步骤(1)中所述溶胀可通过加入DCM实现。步骤(2)可以为常规的氨基酸合成步骤。步骤(3)中洗涤可依次利用DMF、乙醇、DMF、DCM进行。步骤(4)中切割液例如为TFA95％；水1％；EDT 2％；TIS 2％的混合液。
为便于保存，该制备方法还包括将目标多肽进行冻干。
此外，本发明还提供上述高特异性MMP-14底物肽作为基质金属蛋白酶-14检测试剂的应用。
本发明通过一段聚乙二醇(PEG)作为linker在原有的广谱性MMPs多肽底物上连入一段MMP-14的特异性结合多肽，利用多肽的锚定性以及特异性把MMP-14对原有多肽的催化特异性大大提高了。本发明的底物具有高特异性，该底物以多肽及PEG结构为基础，在基质金属蛋白酶检测及癌症检测治疗应用方面具有广阔的前景。
此外，所用的聚乙二醇linker通过了美国FDA认证，符合美国药典(USP)，国家处方集(NF)，食品化学法典(FCC)标准，结构简单且体内安全性高，具有临床应用开发的巨大潜力。
本发明的其它特征和优点将在随后具体实施方式部分予以详细说明。
具体实施方式
通过以下实施例更详细地描述本发明。
所用材料及仪器：
1、树脂：取代度为1.03mmol/g的2-Chlorotrityl Chloride Resin(天津市南开合成科技有限公司)
2、氨基酸：
Fmoc-Leu-OH(成都诚诺，>99％)，Fmoc-Phe-OH(成都诚诺，>99％)，Fmoc-Thr(But)-OH(成都诚诺，>99％)等
3、原料：
Fmoc-NH-PEG24-CH2CH2COOH(博美生物，99％)，Fmoc-Dap(Dnp)-OH(博美生物，99％)，7-甲氧基香豆素-4-乙酸(MCA，百灵威科技，>99.0％)
4、合成试剂：
DMF(原产地韩国)，DCM(原产地韩国)，MEOH(原产地日本)，
DIEA(新德化工，99％)，HBTU(昊帆生物科技，99％)
5、脱保护试剂：
哌啶(国药集团上海化学试剂公司，99％)
6、检测试剂：
苯酚试剂(自配)，吡啶试剂(自配)，茚三酮试剂(自配)
7、裂解试剂：
95％切割液：TFA(J.T.Baker，99％)，TIS(上海达瑞精细化工，98％)，EDT(上海达瑞精细化工，98％)，无水乙醚(上海实验，实测99.7％)
8、氮气：(新联气体)
9、仪器：
十二通道半自动多肽合成仪：上海强耀生物科技有限公司
SHIMADZU高效液相色谱仪(型号：制备型，分析型，软件：Class-VP.SevialSystem，厂商：SHIMADZU)
LABCONCO冻干机(型号：Freezone.Plus.6，厂商：LABCONCO)
离心机(上海安亭科学仪器厂型号：TDL-40B)
实施例1-3
合成顺序：从C端到N端。合成步骤如下：
(1)树脂溶胀
将2-Chlorotrityl Chloride Resin放入反应管中，加DCM(15mL/g)，振荡30min。
(2)接第一个氨基酸
通过沙芯抽滤掉溶剂，加入3倍摩尔过量的Fmoc-Leu-OH氨基酸，加入DMF溶解，再加入10倍摩尔过量的DIEA，振荡60min。用甲醇封闭。
(3)脱保护
去掉DMF，加20％哌啶DMF溶液(15mL/g)，5min，去掉再加20％哌啶DMF溶液(15mL/g)，15min。
(4)检测
抽掉哌啶溶液，取十几粒树脂，用乙醇洗三次，加入检测试剂检测，105℃-110℃加热5min，变深蓝色为阳性反应。
(5)洗涤：DMF(10mL/g)两次，DCM(10mL/g)两次，DMF(10mL/g)两次。
(6)缩合
保护氨基酸三倍过量，HBTU三倍过量，均用尽量少DMF溶解，加入反应管，立刻加入十倍过量的DIEA，反应30min。
(7)检测
取十几粒树脂，用乙醇洗三次，加入检测试剂检测，105℃-110℃加热5min，无色为阴性反应。
(8)洗涤
DMF(10mL/g)一次，DCM(10mL/g)两次，DMF(10mL/g)两次。
(9)重复步骤(3)至步骤(6)，从右到左依次连接序列中的氨基酸，最后接MCA。
(10)抽干，按照下列方法洗树脂：
DMF(10mL/g)两次，甲醇(10mL/g)两次，DMF(10mL/g)两次，DCM(10mL/g)两次，抽干10min。
(11)从树脂上切割多肽
配制切割液(10mL/g)：TFA 95％；水1％；EDT 2％；TIS 2％。
切割时间：120min。
(12)吹干洗涤
将裂解液用氮气尽量吹干，用乙醚洗六次，然后常温挥干。
(13)分析提纯：用高效液相色谱将粗品提纯。
(14)冻干
收集目标多肽溶液放入冻干机中进行浓缩，冻干成白色粉末。
通过质谱检验，证明分别合成产物肽B-肽D，序列如表1所示。
表1
| 多肽名称 | 多肽序列 |
| 肽A | (MCA)-PLGL-(Dpa)-AR |
| 肽B | (MCA)-PLGL-(Dpa)-AR-(PEG)<sub>24</sub>-HWKHLHNTKTFL |
| 肽C | (MCA)-PLGL-(Dpa)-AR-(PEG)<sub>12</sub>-HWKHLHNTKTFL |
| 肽D | (MCA)-PLGL-(Dpa)-AR-(PEG)<sub>6</sub>-HWKHLHNTKTFL |
测试例1
对肽B-肽D以及肽A(通过常规方法合成)进行酶活性检测。检测方法如下：
酶促反应动力学法，具体操作为：在96孔酶标板中依次加入底物肽(1μM)、MMPAssay Buffer(20mM Tris-HCl pH 8.0,150mM NaCl,5mM CaCl2,100μM ZnCl2,0.05％Brij35)与不同浓度的MMP-14，同时以加入MMP-14相同体积的缓冲溶液作为对照组，在反应温度为37℃，激发波长328nm、发射波长393nm的条件下测定单位时间内荧光的变化。
结果如表2所示。
表2
由表2检测结果可见，本发明的底物肽对于MMP-14具有高特异性，特别是具有优选范围聚乙二醇linker的底物肽，催化特异性更为显著。
以上已经描述了本发明的各实施例，上述说明是示例性的，并非穷尽性的，并且也不限于所披露的各实施例。在不偏离所说明的各实施例的范围和精神的情况下，对于本技术领域的普通技术人员来说许多修改和变更都是显而易见的。
SEQUENCE LISTING
<110> 天津医科大学
<120> 高特异性MMP-14底物肽及其制备方法和应用
<130> 1700201
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 4
<212> PRT
<213> 人工序列
<400> 1
Pro Leu Gly Leu
1
<210> 2
<211> 12
<212> PRT
<213> 人工序列
<400> 2
His Trp Lys His Leu His Asn Thr Lys Thr Phe Leu
1 5 10
Claims (5)
1.一种高特异性MMP-14底物肽，其特征在于，该底物肽的结构如式I所示：
其中，n为10-15的整数，F1和F2分别为荧光基团及其对应的淬灭基团。
2.根据权利要求1所述的高特异性MMP-14底物肽，其中，所述底物肽的结构为式II所示，或为式III所示；
其中，p和q均为10-15的整数。
3.权利要求1-2中任意一项所述的高特异性MMP-14底物肽的制备方法，其特征在于，该制备方法包括如下步骤：
合成顺序：从C端到N端；
(1)将2-氯三苯甲基氯树脂进行溶胀；
(2)完成第一个Fmoc保护的氨基酸的连接，随后重复脱保护、检测、洗涤、加入Fmoc保护的氨基酸进行缩合、检测、洗涤的步骤，按所设计序列连入相应的氨基酸，最后接7-甲氧基香豆素-4-乙酸；
(3)抽干并洗涤树脂；
(4)用切割液将多肽从树脂上切割下来；
(5)将裂解液用氮气吹干，多肽用乙醚洗涤，然后常温干燥；
(6)使用HPLC对粗品进行分析提纯。
4.根据权利要求3所述的方法，其中，该制备方法还包括：(7)将目标多肽进行冻干。
5.权利要求1-2中任意一项所述的高特异性MMP-14底物肽在制备基质金属蛋白酶-14检测试剂中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710462607.5A CN107501394B (zh) | 2017-06-19 | 2017-06-19 | 高特异性mmp-14底物肽及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710462607.5A CN107501394B (zh) | 2017-06-19 | 2017-06-19 | 高特异性mmp-14底物肽及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107501394A CN107501394A (zh) | 2017-12-22 |
| CN107501394B true CN107501394B (zh) | 2021-02-26 |
Family
ID=60679467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710462607.5A Active CN107501394B (zh) | 2017-06-19 | 2017-06-19 | 高特异性mmp-14底物肽及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107501394B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101497878A (zh) * | 2008-01-30 | 2009-08-05 | 房学迅 | 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用 |
| CN106163556A (zh) * | 2013-09-25 | 2016-11-23 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
-
2017
- 2017-06-19 CN CN201710462607.5A patent/CN107501394B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101497878A (zh) * | 2008-01-30 | 2009-08-05 | 房学迅 | 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用 |
| CN106163556A (zh) * | 2013-09-25 | 2016-11-23 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
Non-Patent Citations (4)
| Title |
|---|
| High-affinity peptide against MT1-MMP for in vivo tumor imaging;Lei Zhu等;《Journal of Controlled Release》;20110202;第150卷;摘要 * |
| Matrix metalloproteinase-14 is a mechanically regulated activator of secreted MMPs and invasion;Amanda Haag等;《Biochemical and Biophysical Research Communications》;20140527;第450卷;第214页第2.3和3节 * |
| Non-destructive and Selective Imaging of the Functionally Active, Pro-invasive Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Enzyme in Cancer Cells;Albert G. Remacle等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20130712;第288卷(第28期);摘要 * |
| The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells;Guangzhi Gu等;《Biomaterials》;20130409;第34卷;摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107501394A (zh) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eckhard et al. | Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses | |
| US8841085B2 (en) | Nanoparticle sensor for measuring protease activity and method for manufacturing the same | |
| Nagase et al. | Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). | |
| DE69725901T2 (de) | Methode zur bestimmung von proteolytischen enzymen unter benutzung von fluoreszenzgelöschten substraten | |
| Andolfo et al. | Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor | |
| Wijffels et al. | The secreted cathepsin L-like proteinases of the trematode, Fasciola hepatica, contain 3-hydroxyproline residues. | |
| JPWO2010002042A1 (ja) | タンパク質ラベル化用酵素基質 | |
| US6753176B2 (en) | Aggrecan degrading metallo proteases | |
| Rut et al. | Engineered unnatural ubiquitin for optimal detection of deubiquitinating enzymes | |
| US5770691A (en) | Discriminatory substrates for MMP hydrolysis | |
| US9139862B2 (en) | Fluorescent cyclic peptides, preparation method thereof and use of these peptides for measuring the enzymatic activity of a protease enzyme | |
| US20110245147A1 (en) | Activation of Peptide Prodrugs by HK2 | |
| WO2010002976A2 (en) | Enzyme-cleavable dye-containing fluor-quencher constructs | |
| Wu et al. | Separation of enzymatically active and inactive prostate‐specific antigen (PSA) by peptide affinity chromatography | |
| Pakkala et al. | Mimetics of the disulfide bridge between the N-and C-terminal cysteines of the KLK3-stimulating peptide B-2 | |
| CN107501394B (zh) | 高特异性mmp-14底物肽及其制备方法和应用 | |
| FI56525C (fi) | Nya kromogena trombinsubstrat | |
| CN101652149B (zh) | 成像探针 | |
| Rohweder et al. | Multiplex substrate profiling by mass spectrometry for proteases | |
| Koistinen et al. | Development of peptides specifically modulating the activity of KLK2 and KLK3 | |
| US20100047894A1 (en) | Use of Matrix Metalloproteinases, Mutated and Not Mutated, for the Preparation of Pharmaceutical Compositions, and Mutated Metalloproteinases with Increased Stability | |
| Alam et al. | Design and synthesis of a peptidyl-FRET substrate for tumor marker enzyme human matrix metalloprotease-2 (hMMP-2) | |
| KR20110039093A (ko) | 단백질 분해효소 활성 측정용 시험관내 키트 및 그 제조방법 | |
| Ibrahim | Synthesis of Fluorogenic Probes Specific for Matrix Metalloproteinase 13 | |
| SR et al. | Substrate specificity profiling of peptidyl-Lys metallopeptidase of Armillaria mellea by FRET based peptide library |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230828 Address after: Building 4-3, 7-901, Minghai Center, No. 426 Hulunbuir Road, Tianjin Free Trade Pilot Zone (Dongjiang Bonded Port Area), Binhai New Area, Tianjin, 300456 Patentee after: PONUO (TIANJIN) INNOVATIVE MEDICINE RESEARCH Co.,Ltd. Address before: 300070 No. 22 Meteorological Observatory Road, Heping District, Tianjin Patentee before: Tianjin Medical University |